Inari Medical Secures $12.61 Million Investment from Sei Investments Co.

Trending News ☀️

Inari Medical Intrinsic Value – INARI MEDICAL ($NASDAQ:NARI) is a medical device company located in California. The company focuses on developing innovative technologies and products that improve the diagnosis and treatment of cardiovascular diseases. INARI MEDICAL’s mission is to improve the quality of life and health of patients, as well as reduce the cost of healthcare. Recently, INARI MEDICAL has secured a $12.61 million investment from Sei Investments Co. This new investment will enable INARI MEDICAL to continue developing innovative devices and products that can diagnose and treat cardiovascular diseases more effectively. This investment also allows the company to expand its reach to new markets and provide its products to more people around the world.

The investment from Sei Investments Co. will be used to fund research and development of new products, expand into new markets, and increase technology production capabilities. With this additional funding, INARI MEDICAL will be able to make advancements in the healthcare industry by providing more accurate diagnoses and treatments for cardiovascular diseases. The company will also focus on creating more efficient and cost-effective solutions for patients. With this investment, INARI MEDICAL will be able to continue on its mission of improving the quality of life and health of patients, while also reducing the cost of healthcare.

Market Price

On Monday, Inari Medical announced that it had secured a strategic investment of $12.61 million from Sei Investments Co. Following the news, its stock opened at $69.0 and closed at $69.7, up by 1.8% from its previous closing price of 68.4. This latest investment from Sei Investments Co. marks the latest in a series of investments Inari Medical has received in recent months. The company specializes in developing innovative technologies to improve patient outcomes and reduce the cost of healthcare delivery. Inari Medical’s technology portfolio includes products such as its flagship product, the NeuroBlate System, which is a minimally invasive surgical device that uses thermal ablation to treat brain tumors.

Inari is also developing a number of other products, including an interventional radiology suite and a wireless sensor platform for monitoring vital signs. It will also provide additional resources for the company to expand its operations in North America and Europe. Live Quote…

About the Company

VI Analysis – Inari Medical Intrinsic Value Calculator

The VI App simplifies the analysis of the company and its intrinsic value. According to the VI Line, INARI MEDICAL‘s intrinsic value is around $126.1 per share. Currently, the stock is being traded at $69.7, meaning that it is undervalued by 45%. This presents a great opportunity for investors to get in on a company that has great potential. Furthermore, the fundamentals of the company show that it has a strong future, and this makes it an attractive option for investors looking for a long term investment. More…

VI Peers

Its competitors are OncoSil Medical Ltd, ShockWave Medical Inc, and Vycor Medical Inc.

– OncoSil Medical Ltd ($ASX:OSL)

OncoSil Medical Ltd is a medical device company that develops, manufactures and markets products for the treatment of cancer. The company has a market cap of 47.58M as of 2022 and a Return on Equity of -82.6%. OncoSil Medical’s products are designed to target and destroy cancer cells while sparing healthy tissue. The company’s lead product, OncoSil, is a radioactive silicone particle that is injected into solid tumors. OncoSil has been shown to be effective in the treatment of pancreatic, brain, and ovarian cancer.

– ShockWave Medical Inc ($NASDAQ:SWAV)

As of 2022, ShockWave Medical Inc has a market cap of 10.19B and a Return on Equity of 12.48%. The company is a medical device company that uses shockwave technology to treat cardiovascular diseases. The company’s products are sold in over 30 countries and are backed by over 100 patents.

– Vycor Medical Inc ($OTCPK:VYCO)

Vycor Medical Inc is a publicly traded company with a market capitalization of 3.1 million as of 2022. The company has a return on equity of 6.36%, which is relatively high compared to other companies in the same industry. Vycor Medical Inc is a medical device company that specializes in the development and commercialization of minimally invasive products for the neurosurgery market. The company’s products are used by surgeons to treat conditions such as brain tumors, cerebral aneurysms, and skull-base tumors.

Summary

INARI Medical, a medical device company focused on developing solutions to treat and diagnose venous disease, recently announced that it has received a $12.61 million investment from Sei Investments Co. This significant capital infusion will help INARI Medical expand its reach and develop its products even further. This new funding will enable the company to accelerate its development of new products and grow its commercial activities. INARI Medical’s innovative technology, which includes catheters, thrombolytic agents, stents, and guidewires, is designed to improve the diagnosis and treatment of venous diseases. The company plans to use the funds to expand its team, develop new products, and launch clinical trials while also expanding its presence in the United States and other international markets.

This latest investment is just one example of how private investors are recognizing the potential of INARI Medical’s innovative technologies and products. With its proven track record of successful product launches and growing customer base, the company is well-positioned to capitalize on this investment and continue to make a difference in the medical industry.